• Title/Summary/Keyword: 과학 교실

Search Result 1,587, Processing Time 0.027 seconds

Recurrent Ischemic Strokes with Progression of Middle Cerebral Artery Stenosis during HIV Treatment (사람면역결핍바이러스감염증 치료 중 발생한 중대뇌동맥협착의 악화 및 재발성 뇌경색)

  • Kang, Jongsoo;Kim, Min Ok;Yi, Jeong Jin;Park, Min Won;Kim, Chang Hun;Kim, Young-Soo;Park, Kee Hong;Kang, Hee-Young;Choi, Nack-Cheon;Kwon, Oh-Young;Kim, Soo-Kyoung
    • Journal of the Korean neurological association
    • /
    • v.36 no.4
    • /
    • pp.337-340
    • /
    • 2018

  • Human immunodeficiency virus (HIV) infection can result in ischemic stroke via several mechanisms, including opportunistic infection, vasculopathy, cardioembolism, and coagulopathy. HIV-vasculopathy is related to endothelial dysfunction, stenosis and aneurysm formation, infectious vasculitis, dissection and accelerated atherosclerosis during highly active antiretroviral therapy (HAART). We represent a case of HIV infection manifested as an acute ischemic stroke attack. After 4 months during HAART, our patient experienced a recurrent ischemic stroke with progression of middle cerebral artery stenosis.

  • https://doi.org/10.17340/jkna.2018.4.13 인용

Treatment of Atopic Dermatitis (아토피피부염의 치료)

  • Han, Tae-Young;Na, Chan Ho;Lee, Ji Hyun;Kim, Hye One;Park, Chang Ook;Seo, Young Joon;Son, Sang Wook;Shin, Min Kyung;Ahn, Ji Young;Lee, Yang Won;Jang, Yong Hyun;Park, Young Lip;Lew, Bark Lynn
    • Korean journal of dermatology
    • /
    • v.56 no.10
    • /
    • pp.581-593
    • /
    • 2018

  • Atopic dermatitis (AD) is a common, chronic, relapsing, inflammatory skin disease that affects both children and adults. AD is the cause of considerable morbidity including severe pruritus and impaired quality of life. Treatments for active disease include avoidance of triggering factors, barrier repair, topical medications including topical corticosteroids (TCs) and topical calcineurin inhibitors (TCIs), phototherapy, antibacterial agents, and systemic immunosuppressants including cyclosporine. Until recently, the only Food and Drug Administration (FDA)-approved systemic treatment options for patients with moderate-to-severe AD were steroids and cyclosporine. Systemic steroids are not recommended by current guidelines and are commonly associated with disease rebound. Instead, clinicians choose from several off-label immunosuppressants. In 2018, the Korean FDA approved dupilumab for adults with moderate-to-severe AD whose disease is not adequately controlled with topical therapies. The implementation of treatment guidelines for AD is challenging. Herein, we review the several treatment modalities for AD and recommend a treatment algorithm.

  • KSCI